NIH NOTICES

Notice of Change in Expiration Date of PA-17-278 "HIV and Hepatitis B Co-Infection: Advancing HBV Functional Cure through Clinical Research (R21)" (NOT-AI-19-018)
National Cancer Institute

Notice of Change in Expiration Date of PA-17-280 "In Vitro and Animal Model Studies on HBV/HIV Co-Infection (R01)" (NOT-AI-19-020)
National Cancer Institute

Notice of Change in Expiration Date of PA-17-281 "In Vitro and Animal Model Studies on HBV/HIV Co-Infection (R21)" (NOT-AI-19-021)
National Cancer Institute

Notice of NCI Participation in PAR-19-064, Mechanism for Time-Sensitive Drug Abuse Research (R21 Clinical Trial Optional) (NOT-CA-19-015)
National Cancer Institute

Notice of Interest in Long-term Maintenance of Behavior Change Research (NOT-OD-19-040)
National Cancer Institute

Findings of Research Misconduct (NOT-OD-19-041)
National Institutes of Health

Notice of Intent to Publish Funding Opportunity Announcements for Research to Develop, Demonstrate, and Validate Experimental Human Tissue Models that Do Not Rely on Human Fetal Tissue (NOT-OD-19-042)
National Institutes of Health

Advance Notice: Streamlining the Certifications and Representations Process and Phasing out the SF-424B (NOT-OD-19-043)
National Institutes of Health

Notice of Intent to Publish a Funding Opportunity Announcement for Administrative Supplements for Research on Bioethical Issues (NOT-OD-19-045)
National Institutes of Health

Notice: Changes to the NIH Academic Research Enhancement Award (AREA)/R15 Program (NOT-OD-19-015)
National Institutes of Health

Request for Information (RFI): Input on Draft Report from Working Group on Reducing Administrative Burden to Researchers for Animal Care and Use in Research (NOT-OD-19-028)
National Institutes of Health

Notice of Intent to Publish: Cellular Cancer Biology Imaging Research (CCBIR) Program (UM1 Clinical Trial Not Allowed) (NOT-CA-19-016)
National Cancer Institute

National Cancer Institute
JANUARY DEADLINES

Foundation and Other Sources

Sarcoma Foundation of America
Sarcoma Foundation of America Research Grants
Deadline: 1/31/2019
https://www.curesarcoma.org/research/apply-for-a-grant/
About: The Sarcoma Foundation of America has developed a program to provide grants to investigators interested in translational science sarcoma research. In accordance with the mission of the Foundation, research involving the development of novel agents against sarcoma, or research that could potentially lead to the development of novel agents against sarcoma, is eligible for this funding.
Period of Support: 1 year
Funds/Direct Costs: $50,000 total costs for entire period of support
Program Contact: Award Programs
sfagrants@curesarcoma.org

Rally Foundation for Childhood Cancer Research
Collaborative Pediatric Cancer Research Awards Program
Deadline: 1/11/2019
https://rallyfoundation.org/research/become-a-rally-funded-researcher/
About: Rally Foundation for Childhood Cancer Research funds research in the following areas: Under-studied cancer types, innovative approaches to childhood cancer research which could lead to advanced studies or clinical trials, studies that are likely to lead to a clinical trial, personalized, alternative, or integrated research proposals
Period of Support: Up to 2 years
Funds/Direct Costs: Upper $200,000. See announcement for details.
Program Contact: leighanna@rallyfoundation.org

Program Announcements (PA)

National Cancer Institute
Comprehensive Partnerships to Advance Cancer Health Equity (CPACHE) (U54)
Deadline: 01/09/2019
About: This funding opportunity seeks to support the Comprehensive Partnerships to Advance Cancer Health Equity (CPACHE) Program. The CPACHE Program develops and maintains comprehensive, long-term, and mutually beneficial partnerships between institutions serving underserved health disparity population and underrepresented students (ISUPPs) and NCI-designated Cancer Centers (CCs). The program aims to achieve a stronger national cancer program and address challenges in cancer and cancer disparities research, education and outreach, as well as their impact on underserved populations.
Period of Support: Up to 5 years
Funds/Direct Costs: $2 million direct costs per year
Program Contact: H. Nelson Aguila
(240) 276-6170
aguilah@mail.nih.gov

National Cancer Institute
Cancer Research Education Grants Program - Research Experiences (R25)
Deadline: 01/25/2019
About: The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The over-arching goal of this NCI R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation’s biomedical, behavioral and clinical research needs. This FOA will support creative educational activities with a primary focus on Research Experiences.
Period of Support: Up to 5 years
Funds/Direct Costs: $300,000 direct costs per year
Program Contact: Jeannette Korczak
(240) 276-5630
korczakj@mail.nih.gov

National Cancer Institute
Cancer Research Education Grants Program - Courses for Skills Development (R25)
Deadline: 01/25/2019
About: The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The over-arching goal of this NCI R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation’s biomedical, behavioral and clinical research needs. This FOA will support creative educational activities with a primary focus on Courses for Skills Development.
Period of Support: Up to 5 years
Funds/Direct Costs: $300,000 direct costs per year
Program Contact: Jeannette Korczak
(240) 276-5630
korczakj@mail.nih.gov

National Cancer Institute
NCI Research Specialist (Core-based Scientist) Award (R50 Clinical Trial Not Allowed)
Deadline: 1/11/2019
Request for Applications (RFA)

National Cancer Institute

Communication and Decision Making for Individuals with Inherited Cancer Syndromes (U01 Clinical Trial Optional)

Deadline: 1/9/2019

About: The purpose of this FOA is to develop, test, and evaluate interventions and implementation approaches, or adapt existing approaches, to improve patient/provider/family risk communication and decision making for individuals and families with an inherited susceptibility to cancer. This Funding Opportunity Announcement invites U01 applications for projects that develop, test, and evaluate interventions and implementation approaches, or adapt existing approaches, to improve patient/provider/family risk communication and decision making for individuals and families with an inherited susceptibility to cancer so that they can make informed clinical risk management decisions.

Period of Support: Up to 5 years
Funds/Direct Costs: Up to $600,000 in direct costs per year
Program Contact: Wendy Nelson
(240) 276-6971
nelsonw@mail.nih.gov

Multiple Institutes, including the National Cancer Institute

Short Courses on Innovative Methodologies and Approaches in the Behavioral and Social Sciences (R25)

Deadline: 1/24/2019

About: The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The over-arching goal of this IC Name R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation’s biomedical, behavioral and clinical research needs. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on courses for skills development.

Period of Support: Up to 4 years
Funds/Direct Costs: Application budgets are limited to $200,000 in direct costs per year
Program Contact: Jeannette Korczak
(240) 276-5642
korczakj@mail.nih.gov

Multiple Institutes, including the National Cancer Institute

Improving Smoking Cessation Interventions among People Living with HIV (R21)

Deadline: 1/8/2019
About: The goal of this Funding Opportunity Announcement (FOA) is to improve cigarette smoking cessation treatment among people living with HIV (PLWH) in the United States (U.S.), with an emphasis on methodologically rigorous studies that propose to systematically test existing evidence-based smoking cessation interventions (e.g., combination of behavioral and pharmacological) and/or to develop and test adaptations of evidence-based smoking cessation interventions for application to this target population.

Period of Support: 2 years
Funds/Direct Costs: $275,000 direct costs for entire period of support
Program Contact: Annette Kaufman
(240) 276-6706
kaufmana@mail.nih.gov

National Cancer Institute
Approaches to Identify and Care for Individuals with Inherited Cancer Syndromes (U01)
Deadline: 1/9/2019

About: The purpose of this FOA is to increase case ascertainment and appropriate follow-up care, optimizing the delivery of evidence-based healthcare for individuals at high risk of cancer due to an inherited genetic susceptibility.

Period of Support: Up to 5 years
Funds/Direct Costs: Application budgets are not limited but need to reflect the actual needs of the proposed project.
Program Contact: Nonniekaye Shelburne
(240) 276-6897
nshelburne@mail.nih.gov

Intramural Funding Opportunities

Massey Cancer Center
Pilot Research Grant
Pre-Application Deadline: 1/11/2019
Full Application Deadline: 2/12/2019
https://massey.vcu.edu/research/funding/pilot-project-program/

About: VCU Massey Cancer Center offers funding for pilot projects to encourage new collaborative cancer research projects. Massey research members and associate members are eligible to apply. The intent of these pilot projects is to provide initial funding for new, collaborative projects with significant involvement of at least two independent investigators. A major purpose of this program is to allow collaborative research teams the ability to gather preliminary data needed for the investigators to prepare a successful grant application for a larger study. All interested investigators are required to submit a Pre-Application Form prior to submitting a full application.

Period of Support: 1 year
Funds/Direct Costs: Up to $50,000 for entire period of support
Program Contact: Olivia Patterson
(804) 628-1931
opatterson@vcu.edu

FEBRUARY/MARCH DEADLINES

Foundation and Other Sources

American Society for Radiation Oncology
ASTRO-BCRF Career Development Award to End Cancer
Deadline: 2/15/2019
https://www.astro.org/Patient-Care-and-Research/Research/Funding-Opportunities/ASTRO-BCRF-Award

About: The goal of this award is to advance the field of radiation oncology in novel ways through the support of talented early-career scientists performing radiation-oncology related research. The aim is to support the next generation of researchers and to significantly improve outcomes and quality of life for breast cancer patients.

Period of Support: 2 years
Funds/Direct Costs: $100,000 direct costs per year
Program Contact: Scientific Affairs Department
research@astro.org

Leukemia Research Foundation
New Investigator Research Program
Letter of Intent Deadline: 2/1/2019
Full Application Deadline: 3/18/2019
https://www.allbloodcancers.org/guidelines

About: The Leukemia Research Foundation exclusively funds New Investigators - individuals beginning to establish their own laboratories that are no longer under the tutelage of a senior scientist mentor. Preference given to proposals that focus on leukemia, lymphoma, MDS, and multiple myeloma. New Investigators are considered to be within 7 years of their first independent position.

Period of Support: 1 year
Funds/Direct Costs: Up to $100,000
Program Contact: Leukemia Research Foundation
(847) 424-0600
grants@LRFmail.org
NEW
American Cancer Society
Metastasis in Melanoma and Other Cancers
Letter of Intent Deadline: 1/16/2019
Full Application Deadline: 4/15/2019
About: The American Cancer Society (ACS) and the Melanoma Research Alliance (MRA) have partnered to support research. They are requesting grant applications to fund research projects that involve interdisciplinary teams about “Understanding and Managing Metastasis of Melanoma and Other Types of Cancer.” To be considered for this grant on metastasis, proposed research must have at least a 50% focus on melanoma.
Period of Support: Up to 3 years
Funds/Direct Costs: A total of $2 million committed equally by ACS and MRA will be used to fund 2 Team Awards at $1 million, distributed across the term of the grant.
Program Contact: grants@cancer.org

NEW
St. Baldrick's Foundation
Scholar (Career Development) Awards
Deadline: 3/29/2019
About: The Scholar (Career Development) Award is meant to help develop the independent research of highly qualified individuals still early in their careers.
Period of Support: 3 years
Funds/Direct Costs: Up to $110,000 direct costs per year.
Program Contact: St. Baldrick’s Foundation
(626) 792-8247
grants@stbaldricks.org

Damon Runyon Cancer Research Foundation
Clinical Investigator Award
Deadline: 2/1/2019
https://www.damonrunyon.org/for-scientists/application-guidelines/clinical-investigator
About: The Damon Runyon Clinical Investigator Award supports independent young physician-scientists conducting disease-oriented research that demonstrates a high level of innovation and creativity. The goal is to support the best young physician-scientists doing work aimed at improving the practice of cancer medicine.
Period of Support: 3 years
Funds/Direct Costs: $150,000 total costs per year. Indirect costs are not allowed.
Program Contact: Award Programs

(212) 455-0520
awards@damonrunyon.org

Program Announcements (PA)

National Cancer Institute
Modular R01s in Cancer Control and Population Sciences (R01)
Deadline: 03/06/2019
About: This funding opportunity announcement (FOA) encourages applications for research in cancer control and population sciences. The overarching goal is to provide support to promote research efforts on novel scientific ideas that have the potential to substantially advance cancer research in statistical and analytic methods, epidemiology, cancer survivorship, cancer-related behaviors and behavioral interventions, health care delivery, and implementation science.
Period of Support: Up to 5 years
Funds/Direct Costs: $250,000 direct costs per year
Program Contact: Scott Rogers
(240) 276-6932
rogerssc@mail.nih.gov

National Cancer Institute
Integrating Biospecimen Science Approaches into Clinical Assay Development (U01)
Deadline: 03/14/2019
About: This Funding Opportunity Announcement (FOA) will support extramural research to investigate and mitigate challenges facing clinical assay development and subsequent analytical validation due to preanalytical variability in tumor tissue biopsies and blood biospecimens utilized as “liquid biopsies.”
Period of Support: Up to 5 years
Funds/Direct Costs: Application budgets limited to $250,000 direct costs per year
Program Contact: Abhi Rao
(240) 276-5715
abhi.rao@nih.gov

National Cancer Institute
The NCI Transition Career Development Award (K22 Clinical Trial Required)
Deadline: 03/12/2019
About: This Funding Opportunity Announcement (FOA)
supports an NCI program that facilitates the transition of investigators in mentored, non-independent cancer research positions to independent faculty cancer research positions.

**Period of Support:** Up to 3 years  
**Funds/Direct Costs:** Application budgets are composed of salary and other program-related expenses as described in announcement.

**Program Contact:** Sonia Jakowlew  
(240) 276-5630  
jakowles@mail.nih.gov

---

**Multiple Institutes, including the National Cancer Institute**  
**Developing the Therapeutic Potential of the Endocannabinoid System for Pain Treatment (R01 - Clinical Trial Optional)**  
**Deadline:** 2/5/2019  

**About:** The purpose of this Funding Opportunity Announcement (FOA) is to support projects that will elucidate the therapeutic potential of the cannabinoids and endocannabinoid system in the development of mechanism-based therapies for pain.

**Period of Support:** Up to 5 years  
**Funds/Direct Costs:** Application budgets are not limited but need to reflect the actual needs of the proposed project.

**Program Contact:** Ann O'Mara  
(240) 276-7050  
omaraa@mail.nih.gov

---

**National Cancer Institute**  
**The NCI Transition Career Development Award (K22 Clinical Trial Not Allowed)**  
**Deadline:** 03/12/2019  

**About:** This Funding Opportunity Announcement (FOA) supports an NCI program that facilitates the transition of investigators in mentored, non-independent cancer research positions to independent faculty cancer research positions.

**Period of Support:** Up to 3 years  
**Funds/Direct Costs:** Application budgets are composed of salary and other program-related expenses as described in announcement.

**Program Contact:** Sonia Jakowlew  
(240) 276-5630  
jakowles@mail.nih.gov

---

**Multiple Institutes, including the National Cancer Institute**  
**Dissemination and Implementation Research in Health (R21 Clinical Trial Optional)**  
**Deadline:** 2/16/2019  

**About:** This Funding Opportunity Announcement (FOA) encourages investigators to submit research grant applications that will identify, develop, test, evaluate and/or refine strategies to disseminate and implement evidence-based practices (e.g. behavioral interventions; prevention, early detection, diagnostic, treatment and disease management interventions; quality improvement programs) into public health, clinical practice, and community settings. In addition, studies to advance dissemination and implementation research methods and measures are encouraged.

**Period of Support:** Up to 2 years  
**Funds/Direct Costs:** The combined budget for direct costs for the two-year project period may not exceed $275,000.

**Program Contact:** Crystal Wolfrey  
(240) 276-6277  
wolfreyc@mail.nih.gov

---

**Multiple Institutes, including the National Cancer Institute**  
**Quantitative Imaging Tools and Methods for Cancer Response Assessment (R01 Clinical Trial Optional)**  
**Deadline:** 2/5/2019  

**About:** This purpose of this Funding Opportunity Announcement (FOA) is to provide a mechanism of support to research organizations interested in clinically translating already optimized quantitative imaging software tools capable of measuring or predicting the response of cancer to clinical therapies, or in translating imaging software tools for planning and validating radiation therapy treatment strategies in clinical trials. The quantitative tools must have been developed and optimized during a performance period in the Quantitative Imaging Network (QIN) or under other separate funding. The proposed research effort should be an extension of the research that successfully completed the tasks of developing and optimizing the chosen software tools or data collection methods intended to facilitate clinical decision making during clinical trials.

**Period of Support:** Up to 5 years  
**Funds/Direct Costs:** Up to $500,000 in direct costs each year

**Program Contact:** Robert Nordstrom  
(240) 276-5934  
nordstrr@mail.nih.gov
Biobehavioral Basis of Chronic Pain (R21 Clinical Trial Optional)
Deadline: 02/16/2019
About: The purpose of the Funding Opportunity Announcement is to encourage grant applications from the scientific community on the biobehavioral basis of chronic pain. The focus encompasses the individual phenotype, genotype, and other omic-type assessments and the associated sensory and emotional components that underpin the individual’s chronic pain experience.
Period of Support: 2 years
Funds/Direct Costs: $275,000 direct costs for entire period of support
Program Contact: Sean Hine
(240) 276-6291
hines@mail.nih.gov

Multiple Institutes, including the National Cancer Institute
Biobehavioral Basis of Chronic Pain (R01 Clinical Trial Optional)
Deadline: 2/5/2019
About: The purpose of the Funding Opportunity Announcement is to encourage grant applications from the scientific community on the biobehavioral basis of chronic pain. The focus encompasses the individual phenotype, genotype, and other omic-type assessments and the associated sensory and emotional components that underpin the individual’s chronic pain experience.
Period of Support: Up to 5 years
Funds/Direct Costs: Application budgets are not limited but need to reflect the actual needs of the proposed project.
Program Contact: Ann O’Mara
(240) 276-7050
omaraa@mail.nih.gov

Multiple Institutes, including the National Cancer Institute
Increasing Uptake of Evidence-Based Screening in Diverse Adult Populations
Deadline: 2/5/2019
About: This Funding Opportunity Announcement (FOA) invites applications that seek to understand strategies to reduce disparities in the uptake of evidence-based screening (e.g. screening recommendations proven to be effective based on rigorous systematic review of scientific evidence by authoritative committees) across the adult lifespan.
Period of Support: Up to 5 years
Funds/Direct Costs: Application budgets are not limited but need to reflect the actual needs of the proposed project.
Program Contact: Erica Breslau
(240) 276-6773
breslaue@mail.nih.gov

National Cancer Institute
Physical Activity and Weight Control Interventions Among Cancer Survivors: Effects on Biomarkers of Prognosis and Survival (R21)
Deadline: 02/16/2019
About: This Funding Opportunity Announcement (FOA) encourages transdisciplinary and translational research that will identify the specific biological or biobehavioral pathways through which physical activity and/or weight control (either weight loss or avoidance of weight gain) may affect cancer prognosis and survival. Research applications should test the effects of physical activity, alone or in combination with weight control (either weight loss or avoidance of weight gain), on biomarkers of cancer prognosis among cancer survivors identified by previous animal or observational research on established biomarkers other than insulin/glucose metabolism, especially those obtained from tumor tissue sourced from repeat biopsies where available.
Period of Support: 2 years
Funds/Direct Costs: $275,000 direct costs for entire period of support
Program Contact: Frank Perna
(240) 276-6782
pernafm@mail.nih.gov
Multiple Institutes, including the National Cancer Institute
Advancing Translational and Clinical Probiotic/Prebiotic
and Human Microbiome Research (R01)
Deadline: 2/5/2019
About: The purpose of this funding opportunity announcement (FOA) is twofold: 1). to accelerate translational and clinical Phase I and II a/b safety and efficacy studies for substantiating measurable functional benefits of probiotic/prebiotic components and/or their combinations; and; 2). to understand the underlying mechanisms of their action(s), and variability in responses to these interventions.
Period of Support: Up to 5 years
Funds/Direct Costs: Application budgets are not limited but need to reflect the actual needs of the proposed project.
Program Contact: Gabriela Riscuta
(240) 276-7118
gabriela.riscuta@nih.gov

National Cancer Institute
Integration of Imaging and Fluid-Based Tumor Monitoring in Cancer Therapy (R01)
Deadline: 02/05/2019
About: Through this funding opportunity announcement (FOA), the National Cancer Institute (NCI) seeks research project (R01) grant applications describing projects that integrate imaging and fluid-based tumor monitoring (liquid biopsy) assays during cancer therapy in patients to determine the optimal use of those modalities in the characterization of therapy response and/or emergence of resistance.
Period of Support: Up to 5 years
Funds/Direct Costs: $499,999 direct costs per year
Program Contact: Anne Menkens
(240) 276-6510
menkensa@mail.nih.gov

National Cancer Institute
Early-life Factors and Cancer Development Later in Life (R03)
Deadline: 02/16/2019
About: The purpose of this Funding Opportunity Announcement (FOA) is to stimulate research focused on the role of early-life factors (maternal-paternal, in utero, birth and infancy, puberty, adolescence, and young adult years) in cancer development later in life.
Period of Support: Up to 2 years
Funds/Direct Costs: $100,000 direct costs per year
Program Contact: Somdat Mahabir
(240) 276-6941
mahabir@mail.nih.gov

National Cancer Institute
Early-life Factors and Cancer Development Later in Life (R01)
Deadline: 02/05/2019
About: The purpose of this Funding Opportunity Announcement (FOA) is to stimulate research focused on the role of early-life factors (maternal-paternal, in utero, birth and infancy, puberty, adolescence, and young adult years) in cancer development later in life.
Period of Support: Up to 5 years
Funds/Direct Costs: Application budgets are not limited but need to reflect the actual needs of the proposed project.
Program Contact: Somdat Mahabir
(240) 276-6941
mahabir@mail.nih.gov

Multiple Institutes, including the National Cancer Institute
Reducing Overscreening for Breast, Cervical, and Colorectal Cancers among Older Adults (R01)
Deadline: 02/05/2019
About: The purpose of this Funding Opportunity Announcement (FOA) is to promote research on interventions, based in healthcare settings, designed to reduce overscreening for breast, cervical, or colorectal cancers among average-risk older adults.
Period of Support: Up to 5 years
Funds/Direct Costs: Application budgets are not limited but need to reflect the actual needs of the proposed project.
Program Contact: Erica Breslau
(240) 276-6773
breslaue@mail.nih.gov

Multiple Institutes, including the National Cancer Institute
The Interplay of Cell Death Pathways in Cancer Cell Survival and Resistance to Therapy (R21)
Deadline: 02/16/2019
About: The purpose of this funding opportunity announcement (FOA) is to stimulate research in the interplay between cell death pathways in naive and drug resistant cancers.
**National Cancer Institute**

**Discovery of Small Molecule Immunomodulators for Cancer Therapy (R01)**

**Deadline:** 02/05/2019  

**About:** The purpose of this funding opportunity announcement (FOA) is to promote the discovery of novel small molecules that may enhance the ability of the immune system to selectively recognize and attack cancer cells. This FOA encourages the design of research projects that utilize the following phases of discovery research: 1) assay development specifically designed for immunoncology targets with the intent to screen for novel small molecule compounds that show potential as either probes or drugs, or as pre-therapeutic leads; 2) screen implementation for immunomodulatory targets to identify initial screening hits; 3) hit validation through secondary orthogonal and counter screening assays, and hit prioritization; and 4) hit-to-lead optimization.

**Period of Support:** Up to 4 years  
**Funds/Direct Costs:** Application budgets are not limited but need to reflect the actual needs of the proposed project.

**Program Contact:** Sundar Venkatachalam  
(240) 276-7304  
sundarv@nih.gov

---

**Multiple Institutes, including the National Cancer Institute**

**End-of-Life and Palliative Care Approaches to Advanced Signs and Symptoms (R21)**

**Deadline:** 02/16/2019  

**About:** The purpose of this funding opportunity announcement (FOA) is to stimulate research to examine the multi-dimensional foundations, experiences and management of complex, advanced signs and symptoms at the end of life.

**Period of Support:** Up to 2 years  
**Funds/Direct Costs:** $275,000 direct costs for entire period of support

**Program Contact:** Karen Kehl  
(301) 594-8010  
kehlka@nih.gov

---

**Multiple Institutes, including the National Cancer Institute**

**Research Project Grant (Parent R01)**

**Deadline:** 02/05/2019  

**About:** The NIH Research Project Grant supports a discrete, specified, circumscribed project in areas representing the specific interests and competencies of the investigator(s). The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions.

**Period of Support:** Up to 5 years  
**Funds/Direct Costs:** Application budgets are not limited but need to reflect the actual needs of the proposed project.

**Program Contact:** Crystal Wolfrey  
(240) 276-6277  
wolfreyC@mail.nih.gov

---

**National Cancer Institute**

**Leveraging Population-based Cancer Registry Data to Study Health Disparities (R01)**

**Deadline:** 02/05/2019  

**About:** The goal of this Funding Opportunity Announcement (FOA) is to efficiently use the existing cancer registry infrastructure by augmenting data already collected with additional information needed to understand health disparities among people diagnosed with cancer. Specifically, this FOA will support the study of factors influencing observed health disparities within the framework of population-based cancer registries by the inclusion of data not routinely collected by or linked to the registries.

**Period of Support:** Up to 5 years  
**Funds/Direct Costs:** Application budgets are not limited but need to reflect the actual needs of the proposed project.

**Program Contact:** Kathleen Cronin  
(240) 276-6836  
cronink@mail.nih.gov

---

**National Cancer Institute**

**Physical Activity and Weight Control Interventions Among Cancer Survivors: Effects on Biomarkers of Prognosis and Survival (R01 Clinical Trial Optional)**

**Deadline:** 02/05/2019  

**About:** This Funding Opportunity Announcement (FOA) encourages transdisciplinary and translational research that will identify the specific biological or biobehavioral pathways through which physical activity and/or weight control (either weight loss or avoidance of weight gain) may affect cancer prognosis and survival. Research applications...
should test the effects of physical activity, alone or in combination with weight control (either weight loss or avoidance of weight gain), on biomarkers of cancer prognosis among cancer survivors identified by previous animal or observational research on established biomarkers other than insulin/glucose metabolism, especially those obtained from tumor tissue sourced from repeat biopsies where available.

**Period of Support:** Up to 5 years  
**Funds/Direct Costs:** Application budgets are not limited but need to reflect the actual needs of the proposed project.  
**Program Contact:** Frank Perna  
(240) 276-6782  
pernafm@mail.nih.gov

---

**National Cancer Institute**  
**Traceback Testing: Increasing Identification and Genetic Counseling of Mutation Carriers through Family-based Outreach (U01 Clinical Trial Optional)**  
**Deadline:** 02/05/2019  
**About:** The purpose of the Funding Opportunity Announcement (FOA) is to support pilot research projects using a "Traceback" approach to genetic testing women with a personal or family history of ovarian cancer and reaching out to family members to identify unaffected individuals at increased risk for cancer in different clinical contexts and communities, including racially/ethnically diverse populations.  
**Period of Support:** Up to 4 years  
**Funds/Direct Costs:** Application budgets are not limited but need to reflect the actual needs of the proposed project.  
**Program Contact:** Goli Samimi  
(301) 276-6582  
golisamimi@nih.gov

---

**National Cancer Institute**  
**Oral Anticancer Agents: Utilization, Adherence, and Health Care Delivery (R21 Clinical Trial Optional)**  
**Deadline:** 02/16/2019  
**About:** The purpose of this funding opportunity announcement (FOA) is to encourage exploratory/developmental research grant applications to: (1) assess and describe the current state of oral anticancer medication utilization, delivery, and adherence; (2) identify structural, systemic, and psychosocial barriers to adherence; and (3) develop models and strategies to improve safe and effective delivery of these agents so that clinical outcomes are optimized.  
**Period of Support:** Up to 2 years  
**Funds/Direct Costs:** The combined budget for direct costs for the two-year project period may not exceed $275,000.  
**Program Contact:** Wendy Nelson  
(240) 276-6971  
nelsonw@mail.nih.gov

---

**Multiple Institutes, including the National Cancer Institute**  
**Advancing the Science of Geriatric Palliative Care (R21 - Clinical Trial Optional)**  
**Deadline:** 02/16/2019
Multiple Institutes, including the National Cancer Institute
End-of-Life and Palliative Care Health Literacy: Improving Outcomes in Serious, Advanced Illness (R01 Clinical Trial Optional)
Deadline: 02/05/2019

About: This funding opportunity announcement (FOA) seeks to stimulate research focused on identification of the key barriers to effective end-of-life and palliative care (EOLPC) health literacy in diverse settings and populations, and to create novel strategies, interventions, and models of care to improve EOLPC health literacy, with the goal of improving outcomes for individuals with serious, advanced illness and their families and caregivers.

Period of Support: Up to 5 years
Funds/Direct Costs: Application budgets are not limited but need to reflect the actual needs of the proposed project.
Program Contact: Wen-Ying Sylvia Chou
(240) 276-6954
chouws@mail.nih.gov

National Cancer Institute
Multilevel Interventions in Cancer Care Delivery: Follow-up to Abnormal Screening Tests (R01 Clinical Trial Optional)
Deadline: 02/05/2019
https://grants.nih.gov/grants/guide/pa-files/PA-17-495.html

About: This Funding Opportunity Announcement (FOA) encourages applications that develop and test multilevel interventions to improve follow-up to abnormal screening tests for breast, cervical, colorectal, or lung cancers.

Period of Support: Up to 5 years
Funds/Direct Costs: The combined budget for direct costs for the two-year project period may not exceed $275,000.
Program Contact: Ann M. O’Mara
(240) 276-7050
omaraa@mail.nih.gov

NEW
National Cancer Institute
Improving Outcomes in Cancer Treatment-Related Cardiotoxicity (R21)
Deadline: 02/16/2019

About: This Funding Opportunity Announcement (FOA) encourages collaborative applications that will contribute to the identification and characterization of patients at risk of developing cancer treatment-related cardiotoxicity. The primary intent is to mitigate cardiovascular dysfunction while optimizing cancer outcomes.

Period of Support: Up to 2 years
Funds/Direct Costs: The combined budget for direct costs for the entire project period may not exceed $275,000.
Program Contact: Nonniekaye Shelburne
(240) 276-6897
nshelburne@mail.nih.gov

NEW
Multiple Institutes, including the National Cancer Institute
End-of-Life and Palliative Needs of Adolescents and Young Adults (AYA) with Serious Illnesses (R01)
Deadline: 02/05/2019

About: The purpose of this funding opportunity announcement (FOA) is to foster research on the unique perspectives, needs, wishes, and decision-making processes of adolescents and young adults (AYA; defined by the World Health Organization and the Centers for Disease Control and Prevention as youth between 12–24 years of age) with serious, advanced illnesses; and research focused on specific end-of-life/palliative care (EOLPC) models that support the physical, psychological, spiritual, and social needs of AYA with serious illness, their families and caregivers.

Period of Support: Up to 5 years
Funds/Direct Costs: Application budgets are not limited but need to reflect the actual needs of the proposed project.
Program Contact: Lynn Adams
(301) 594-8911
lynn.adams@nih.gov

National Cancer Institute
Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH2/UH3 Clinical Trial Not Allowed)
Deadline: 02/13/2019
About: The purpose of this Funding Opportunity Announcement (FOA) is to support the validation of molecular/cellular/imaging markers and assays for cancer detection, diagnosis, prognosis, monitoring, and prediction of response or resistance to treatment, as well as markers for cancer prevention and control.
Period of Support: Up to 3 years
Funds/Direct Costs: Applicants may request up to $275,000 direct costs for the entire UH2 phase with no more than $200,000 requested in any one year and up to $250,000 direct costs for the UH3 phase per year.
Program Contact: Tracy G. Lively
(240) 276-5944
livelyt@mail.nih.gov

Multiple Institutes, including the National Cancer Institute
Mechanisms of Disparities in Etiology and Outcomes of Lung Cancer in the U.S.: The Role of Risk and Protective Factors (R21)
Deadline: 03/04/2019
About: This initiative will support exploratory and developmental multidisciplinary research to understand the underlying causal factors and mechanisms that result in lung cancer disparities in U.S. health disparity populations.
Period of Support: 2 years
Funds/Direct Costs: $275,000 direct costs for entire period of support
Program Contact: Anil Wali
(240) 276-6183
walia@mail.nih.gov

Multiple Institutes, including the National Cancer Institute
Leveraging Health Information Technology (Health IT) to Address Minority Health and Health Disparities (R01 Clinical Trial Optional)
Deadline: 03/04/2019
About: This funding opportunity announcement (FOA) seeks to support research that examines how health information technology adoption impacts minority health and health disparity populations in access to care, quality of care, patient engagement, and health outcomes.
Period of Support: Up to 5 years
Funds/Direct Costs: Application budgets are not limited but need to reflect the actual needs of the proposed project.
Program Contact: April Oh
(240) 276-6709
April.oh@mail.nih.gov

Request for Applications (RFA)
National Cancer Institute
Implementation Science for Cancer Control: Developing Centers (P50 Clinical Trial Optional)
Deadline: 2/11/2019
About: The purpose of this FOA is to support P50 Developing Centers that will build research capacity to study high priority areas of cancer control implementation science, build implementation laboratories, improve the state of measurement and methods, and improve the adoption, implementation, and sustainment of evidence-based cancer control interventions. Specifically, this FOA
targets the following areas designated as scientific priorities by the Blue Ribbon Panel (BRP): Prevention and Screening: Implementation of Evidence-based Approaches; Symptom Management, Prevention and Screening: High-Risk Cancers and other cross-cutting Moonshot priorities.

**Period of Support:** Up to 5 years  
**Funds/Direct Costs:** Budget is limited to $600,000 in direct costs per year.

**Program Contact:** April Oh  
(240) 276-6709  
ohay@mail.nih.gov

---

**National Cancer Institute**  
**Innovative Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R21)**  
**Deadline:** 03/07/2019  

**About:** This Funding Opportunity Announcement (FOA) solicits grant applications proposing exploratory research projects focused on the early-stage development of highly innovative technologies offering novel molecular or cellular analysis capabilities for basic or clinical cancer research. The emphasis of this FOA is on supporting the development of novel capabilities involving a high degree of technical innovation for targeting, probing, or assessing molecular and cellular features of cancer biology.

**Period of Support:** Up to 3 years  
**Funds/Direct Costs:** Direct costs are limited to $400,000 over a 3-year period, with no more than $200,000 in direct costs allowed in any single year.

**Program Contact:** Tony Dickherber  
(301) 547-9980  
dickherberaj@mail.nih.gov

---

**National Cancer Institute**  
**Accelerating Colorectal Cancer Screening and follow-up through Implementation Science (ACCSIS, Second Wave) (U3G/UH3)**  
**Deadline:** 2/11/2019  

**About:** The purpose of this FOA is to promote research in colorectal cancer (CRC) screening, follow-up, and referral-to-care in regions of the United States (U.S.) where screening rates are below national standards. Specifically, this FOA targets the following area designated as a scientific priority by the Blue Ribbon Panel (BRP): Prevention and Screening: Implementation of Evidence-based approaches.

**Period of Support:** Up to 5 years  
**Funds/Direct Costs:** Up to $500,000 in direct costs per year for UG3, $800,000 in direct costs per year for UH3

**Program Contact:** Sarah Kobrin  
(240) 276-6931  
sarah.kobrin@nih.gov

---

**Multiple Institutes, including the National Cancer Institute**  
**Tobacco Regulatory Science Small Grant Program for New Investigators (R03 Clinical Trial Optional)**  
**Deadline:** 03/07/2019  

**About:** The purpose of this FOA is to support New Investigators in the biomedical, behavioral, and social sciences who are in the early stages of establishing independent careers in tobacco regulatory research. The R03 grant mechanism supports different types of projects including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology.

**Period of Support:** Up to 2 years  
**Funds/Direct Costs:** Application budgets are limited to $50,000 in direct cost per year

**Program Contact:** Rachel Grana Mayne  
(240) 276-5899  
granar@nih.gov

---

**Multiple Institutes, including the National Cancer Institute**  
**Immuno-Oncology Translation Network (IOTN): Immuno-engineering to Improve Immunotherapy (i3) Centers (U54)**  
**Deadline:** 2/11/2019  

**About:** The purpose of this FOA is to develop Immuno-engineering to Improve Immunotherapy (i3) Centers, as new components of the Immuno-Oncology Translation Network (IOTN). The i3 Centers will be comprised of multidisciplinary teams focused on developing and employing engineered immunotherapy approaches to design more durable, widely accessible, and less toxic immunoprevention and immunotherapy strategies.

**Period of Support:** Up to 5 years  
**Funds/Direct Costs:** Up to $900,000 in direct costs per year

**Program Contact:** Kevin Howcroft  
(240) 276-6702  
howcroftk@mail.nih.gov

---

**NEW**  
**National Cancer Institute**  
**NCI Pathway to Independence Award for Outstanding Early Stage Postdoctoral Researchers (K99/R00 Independent Clinical Trial Not Allowed)**  
**Deadline:** 02/26/2019  
About: The purpose of the NCI Pathway to Independence Award for Outstanding Early Stage Postdoctoral Fellows (K99/R00) program is to increase and maintain a strong cohort of new and talented, NCI-supported, independent investigators. This program is designed for postdoctoral fellows with research and/or clinical doctoral degrees who do not require an extended period of mentored research training beyond their doctoral degrees. The objective of this award is to facilitate a timely transition of these fellows from their mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions.

Period of Support: Up to 5 years
Funds/Direct Costs: Award budgets are composed of salary and other program-related expenses, as described in announcement.
Program Contact: Michele McGuirl, PhD
(240) 276-5421
mcguirlma@mail.nih.gov

National Cancer Institute
Immuuno-Oncology Translation Network (IOTN): Cancer Immunoprevention Research Projects (UG3/UH3)

Deadline: 2/11/2019

About: The goal of this FOA is to foster collaborative team science approaches to accelerate the discovery of new immune targets and evaluate novel immune-based therapies and combination approaches that eliminate established cancers in adults or to prevent cancers before they occur. The purpose of this FOA is to support UG3/UH3 phased award Projects as part of the expanded Immuno-Oncology Translational Network (IOTN).

Period of Support: Up to 3 years
Funds/Direct Costs: Up to $500,000 direct costs per year for both the UG3 phase and the UH3 phase
Program Contact: Robert Shoemaker
(240) 276-7077
shoemakr@mail.nih.gov

Multiple Institutes, including the National Cancer Institute
Analytical and/or Clinical Validation of a Candidate Biomarker for Pain (R61/R33 Clinical Trial Optional)

Deadline: 03/07/2019

About: The overarching purpose of this Funding Opportunity Announcement (FOA) is to promote the validation of strong candidate biomarkers and endpoints for pain that can be used to facilitate the development of non-opioid pain therapeutics from discovery through Phase II clinical trials.

Period of Support: Up to 5 years
Funds/Direct Costs: Application budgets are not limited but need to reflect the actual needs of the proposed project.
Program Contact: Ann O’Mara
(301) 496-8541
omalara@mail.nih.gov

National Cancer Institute
Advanced Development and Validation of Emerging Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R33)

Deadline: 03/07/2019

About: This Funding Opportunity Announcement (FOA) solicits grant applications proposing exploratory research projects focused on further development and validation of emerging technologies offering novel capabilities for targeting, probing, or assessing molecular and cellular features of cancer biology for basic or clinical cancer research.

Period of Support: Up to 3 years
Funds/Direct Costs: Direct costs are limited to $300,000 per year.
Program Contact: Tony Dickherber
(301) 547-9980
dickherberaj@mail.nih.gov

Multiple Institutes, including the National Cancer Institute
Innovative Biospecimen Science Technologies for Basic and Clinical Cancer Research (R21)

Deadline: 03/07/2019

Funds/Direct Costs: The combined budget for direct costs for the entire project period may not exceed $275,000.
Program Contact: Carol Perry
(301) 613-5228
perryc@nih.gov
**About:** This Funding Opportunity Announcement (FOA) solicits grant applications proposing exploratory research projects focused on the early-stage development of highly innovative technologies that improve the quality of the samples used for cancer research or clinical care. This includes new capabilities to address issues related to pre-analytical degradation of targeted analytes during the collection, processing, handling, and/or storage of cancer-relevant biospecimens.

**Period of Support:** Up to 3 years

**Funds/Direct Costs:** Direct costs are limited to $400,000 over a 3-year period, with no more than $200,000 in direct costs allowed in any single year.

**Program Contact:** Tony Dickherber  
(301) 547-9980  
dickherberaj@mail.nih.gov

---

**Intramural Funding Opportunities**

**Massey Cancer Center**  
**ACS Institutional Research Grant**

**Deadline:** 2/1/2019  
[https://www.massey.vcu.edu/research/funding/acs-institutional-research-grants/](https://www.massey.vcu.edu/research/funding/acs-institutional-research-grants/)

**About:** The American Cancer Society has awarded an Institutional Research Grant to Virginia Commonwealth University, Massey Cancer Center. Grant applications are now being invited from junior faculty for the award of small research grants of up to $30,000 for one year to perform basic, pre-clinical, clinical and cancer-control research studies (including but not limited to health services, psychosocial/behavioral, epidemiologic and health policy/outcome cancer research). These grants are intended for new investigators (within six years of first independent academic appointment) who do not have an active, nationally competitive research grant (e.g., from NIH, NSF, ACS).

**Period of Support:** 1 year

**Funds/Direct Costs:** $30,000 for entire period of support

**Program Contact:** Olivia Patterson  
(804) 628-1931  
opatterson@vcu.edu